While Hsp70-based vaccines and NK cell therapies would make use of antitumor properties of extracellular Hsp70, targeting intracellular Hsp70 by inhibitors in conventional anticancer treatments generally attacks pro-tumor and antitumor activities of Hsp70. The gene discussed is HSPA1A; the disease is neoplasm.